FGF-2 Polyclonal Antibody
¥680.00
- 产品信息
商品描述
靶点-Target
MRCKα
反应性
Human,Mouse,Rat
应用
WB,ELISA,IHC
宿主物种-Host Species
Rabbit
同种型-Isotype
IgG
修饰-Modification
Unmodified
MW(Observed)
200kD
推荐稀释比
WB 1:500-2000;IHC 1:50-300;ELISA 1:2000-20000
组成
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
纯化工艺
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
储存
-15°C to -25°C/1 year(Do not lower than -25°C)
浓度
1 mg/ml
克隆性
Polyclonal
免疫原
Synthesized peptide derived from the Internal region of human MRCKα. AA range: 580-660
特异性
MRCKα Polyclonal Antibody detects endogenous levels of MRCKα protein.
基因名称
CDC42BPA
蛋白名称
Serine/threonine-protein kinase MRCK alpha
别名
CDC42BPA;KIAA0451;Serine/threonine-protein kinase MRCK alpha;CDC42-binding protein kinase alpha;DMPK-like alpha;Myotonic dystrophy kinase-related CDC42-binding kinase alpha;MRCK alpha;Myotonic dystrophy protein kinase-like alpha
Organism-1
Human
基因ID-1
8476
SwissProt-1
Q5VT25
Organism-2
Mouse
SwissProt-2
Q3UU96
Organism-3
Rat
基因ID-3
114116
SwissProt-3
O54874
背景
The protein encoded by this gene is a member of the Serine/Threonine protein kinase family. This kinase contains multiple functional domains. Its kinase domain is highly similar to that of the myotonic dystrophy protein kinase (DMPK). This kinase also contains a Rac interactive binding (CRIB) domain, and has been shown to bind CDC42. It may function as a CDC42 downstream effector mediating CDC42 induced peripheral actin formation, and promoting cytoskeletal reorganization. Multiple alternatively spliced transcript variants have been described, and the full-length nature of two of them has been reported. [provided by RefSeq, Jul 2008],
细胞定位
Cytoplasm . Cell projection, lamellipodium . Displays a dispersed punctate distribution and concentrates along the cell periphery, especially at the leading edge and cell-cell junction. This concentration is PH-domain dependent. Localizes in the lamellipodium in a FAM89B/LRAP25-dependent manner. .
